On The Pen With Dave Knapp cover art

On The Pen With Dave Knapp

On The Pen With Dave Knapp

By: Bleav Dave Knapp Founder of On The Pen
Listen for free

About this listen

 Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!© 2025 On The Pen With Dave Knapp Hygiene & Healthy Living Physical Illness & Disease Politics & Government
Episodes
  • Wegovy Pill Approved: First Ever GLP-1 Pill, As Good as Injections!

    Wegovy Pill Approved: First Ever GLP-1 Pill, As Good as Injections!
    Dec 23 2025

    https://www.OTPLinks.com


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    29 mins
  • GLP-1 Compound Legislation: States are the Next Battlefield w/ Sabina Hemme

    GLP-1 Compound Legislation: States are the Next Battlefield w/ Sabina Hemme
    Dec 19 2025

    Pharma Influence & Why Patient Voices Matter
    Lobbying Power: Eli Lilly, Novo Nordisk, and Government Access
    Why GLP-1 Medication Access Is at Risk
    Introducing Sabina Hemi & the Mission of GLP Winner
    Why Compounded GLP-1s Matter for Real Patients
    The Federal “Safe Drugs” Bill: What It Claims vs What It Does
    Why This Bill Raises Red Flags for Patients
    What Real Compounding Safety Reform Would Look Like
    How Compounding Pharmacies Are Actually Regulated Today
    Prescription Reporting vs Patient Safety
    Is This Bill About Safety or Litigation Data?
    Dose Flexibility, Personalized Medicine, and Compounding
    Florida SB 860: A Direct Threat to Compounded GLP-1s
    Why Florida Compounding Impacts the Entire Country
    Why Obesity Medications Are Being Singled Out
    Active Pharmaceutical Ingredients (API): What Patients Should Know
    FDA Oversight, the “Green List,” and State Overreach
    Why Florida’s API & COA Requirements Don’t Add Up
    FDA Inspection Backlogs & Impossible Compliance Standards
    Branded Drug Safety Issues vs Compounding Scrutiny
    Catalent, Novo Nordisk, and Manufacturing Concerns
    Counterfeit Ozempic: The Overlooked Safety Crisis
    Why Supply Chain Integrity Should Be the Priority
    What Patients Can Do Right Now
    Petitions, Advocacy, and Making Your Voice Heard
    Florida Residents: Why Local Action Matters
    Final Thoughts on Access, Power, and Patient Advocacy


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    59 mins
  • Compounded Retatrutide? What the Judge Said

    Compounded Retatrutide? What the Judge Said
    Dec 16 2025
    Retatrutide is years away from FDA approval and yet the fight over access, price, control of this medication is already well underway. That's what this podcast is going to be about today. There's well over a hundred thousand people by my estimates who are already on some form of this medication today. And that should tell you enough about how disruptive this molecule is and will be. It is a game changer among game changer. We've been talking about it for three years here at On The Pen, well before any of your favorite gym bros were talking about Retatrutide. We were talking about Reta, who tried Retatrutide here at On The Pen. And that's because we identified this triple agonist as a game changer among game changers. So This is going to be a very Retatrutide heavy episode, and so I hope you'll join us and stick with us if this is a topic you enjoy, because I think this is really going to effectively lay the groundwork for what accessibility to this medication will look like. So let's get into it. Welcome to the On The Pen Podcast with your host, Dave Knapp. Welcome to the On The Pen, the weekly dose podcast. This is our weekly roundup in incretin memetic news. And frankly, there's no news that is bigger than Reta-Trutide news. Just find me any news that is bigger than the data that we got on Reta-Trutide. Now, we already did a video about the Triumph Phase II clinical trials that we got in osteoarthritis of the knee. You can go back and check out that video if you'd like more data. So we're not gonna super... rehash the data. We'll go over at a high level what the data showed us. We're not going to go over how the medicine works, because by now we all know that it's the triple agonist, right? If terzapatide was a dual agonist, GLP-GIP, Retatrutide is the triple agonist that adds to it a glucagon component, which is absolutely just shredding, shredding liver fat. It is absolutely revving up people's metabolism and showing a tremendous amount of weight loss. So let's get into what the weight loss looked like in this first trial, because there are longer obesity trials where, where the primary outcome is the weight loss this was again a specific trial in measuring pain reduction in folks with osteoarthritis of the knee but check out these numbers these are placebo adjusted meaning it's taking the two percent out that people lost on placebo but looking at these numbers Folks on one milligram over forty eight weeks lost seventeen percent. They bumped up to four milligrams. Those folks lost twenty two percent. So right there at the lowest dose, you're already reaching the efficacy of today's drugs that are on the market, like triseptide and semaglutide in their various forms. If you bumped up to eight milligrams, you saw twenty four percent placebo adjusted weight loss and at twelve milligrams, twenty six point four percent weight loss. Adding back in that two percent of the placebo that those on placebo loss, that's twenty eight point four percent weight loss in these forty eight weeks at the highest dose. When you adjust for some of the more real world outcomes, you kind of ding the numbers a little bit based upon people who quit the drug, et cetera. Those numbers look more like a twenty percent weight loss and twenty three point seven percent weight loss at the highest dose. But even then, you're still seeing a drug that is better than the current drugs that are on the market. around forty eight percent of patients on Retatrutide lost greater than twenty five percent. And then if you were at that twelve twelve milligram dose, that highest dose patients lost fifty nine percent of patients lost more than twenty five percent of their body weight. There was a subset that lost thirty percent of their body weight and some even over thirty five percent of their body weight on Retatrutide. So the lower doses compete with today's best drugs and the upper doses are entering into bariatric surgery level weight loss. And that's putting the whole obesity system on notice and probably a lot of surgeons nervous because typical body weight loss was something like the street sleeve gastrectomy. For example, it's about eighteen to twenty five percent body weight. The Roux-en-Y gastric bypass twenty five to thirty five percent weight loss or the duodenal switch thirty to forty percent weight loss. So the upper doses of Ritutrutide overlap with sleeve and bypass outcomes without any surgery. It's incredible. It is a game changer among game changer. It is the new benchmark in obesity medicine. And there's actually more data, like I said, landing in later twenty twenty six. The longer duration will historically, if history is a marker, equal more weight loss than we even see here at this forty eight weeks. We have an interview that will be airing later this week on our channel and on our podcast with our friend Mimi from Australia who just wrapped up her clinical trial on Retatrutide. They ended it like ten weeks early on her,...
    Show More Show Less
    29 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.